Conference
Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).
Abstract
386
Background: Trials of salvage therapy for advanced UC have required prior platinum-based therapy. This practice requires scrutiny since non-platinum-based first-line therapy may be offered to cisplatin-ineligible patients (pts). We examined the impact of prior exposure to first-line platinum vs. non-platinum based chemotherapy on overall survival (OS) with salvage systemic chemotherapy. Methods: Data of pts receiving …
Authors
Sonpavde G; Pond GR; di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K
Volume
34
Pagination
pp. 386-386
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 10, 2016
DOI
10.1200/jco.2016.34.2_suppl.386
Conference proceedings
Journal of Clinical Oncology
Issue
2_suppl
ISSN
0732-183X